Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Abstract Background Primary central nervous system lymphoma (PCNSL) is a rare but aggressive non-Hodgkin lymphoma with limited prospective data to guide optimal therapy. This study evaluates real-world treatment patterns and survival outcomes using a large national cohort. Methods We analyzed data from the National Cancer Database (NCDB) for patients diagnosed with PCNSL between 2004 and 2020. Baseline demographics and treatment characteristics were analyzed using descriptive statistics. Survival outcomes were estimated using the Kaplan-Meier method and compared using log-rank tests. Multivariable Cox proportional hazards models were constructed to identify independent predictors of overall survival (OS). Results A total of 14,450 patients with PCNSL were included; 14,439 had first-line treatment data available, and 13,390 had survival data. Median age at diagnosis was 67 years (range 18-90), 49.2% were female, and 6.6% were African American. Chemotherapy alone was the modality of treatment for 81.6% (n=11,787), 12.2% (n=1,769) received chemoradiation, 3.8% (n=545) received chemotherapy and underwent autologous stem cell transplant (ASCT) but no radiation, and 2.4% (n=348) received radiation only. The median follow-up time was 73.5 months (95% CI 71.4-75.6), and the median OS for the group was 17.4 months (95% CI 16.2-18.6). Survival differed significantly by age group (median OS: 65 yrs, 46.1 months 95% CI 41.7 -50.6; 65-79 yrs, 12.5 months 95% CI 11.2-13.7; ≥80 yrs, 3.2 months 95% CI 2.9-3.5; p0.001), by year of diagnosis (median OS: 2004-2009, 11.0 months 95% CI 9.9-12.1; 2010-2015, 20.0 months 95% CI 17.4-22.6, 2016-2020, 29.7 months 95% CI 26.0-33.4; p0.001), and by frontline treatment strategy (p0.001). Patients treated with chemotherapy followed by ASCT had the longest median OS (not reached), while those receiving radiation alone had the poorest outcomes with a median OS of 3.9 months (95% CI 3.2-4.7); chemoradiation patients had a median OS of 31.8 months (95% CI 27.5-36.1), and chemotherapy only patients had a median OS of 13.9 months (95% CI 12.7-15.1)(p0.001). African American patients had an inferior outcome with a median OS of 10.2 months 95% CI 7.2-13.1, compared to “other” races with a median OS of 36.9 months 95% CI 27.6-46.1 (p0.001), although this is more similar to the median outcome for white patients (17.0 months 95% CI 15.8-18.3). Treatment at an academic center (25.7 vs 11.0 months) and a high case-volume center (defined as median number of cases per facility) (18.6 vs 10.5 months), and lower Charlson-Deyo comorbidity scores (CDS) (defined as CDS 0-1) (21.7 vs 6.8 months) were also associated with superior OS (p0.001). In multivariable analysis, increasing age ( 65-79 y.o HR 1.60 1.52-1.1.68, ≥80 y.o HR 2.95 2.75-3.17), CDS≥2 (HR 1.36 1.28-1.44), and African American race (HR 1.12 1.02-1.24) were adverse predictors of OS (all p0.001), while treatment strategy (ASCT HR 0.17, chemoradiation HR 0.53, chemotherapy only HR 0.68 compared to radiation alone), more recent year of diagnosis (2010-2015 HR 0.81, 2016-2020 0.70), and treatment at an academic center HR 0.81 remained predictors of superior OS (all p0.001). Conclusion In this large national cohort of patients with PCNSL, treatment with chemotherapy followed by ASCT was associated with the most favorable survival outcomes. Patients treated with chemoradiation or multi-agent chemotherapy also demonstrated improved survival compared to those receiving radiation monotherapy or single-agent chemotherapy alone, respectively. Age, comorbidities, race, and treatment at academic centers were also significant independent predictors of OS. These findings highlight substantial disparities in outcomes and underscore the importance of optimizing treatment strategies, improving access to high-intensity therapies, and supporting timely referral to academic or high case-volume centers, particularly for younger and medically fit patients.